Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bausch Health Companies Inc. Common Stock (NY:BHC)

6.280 -0.340 (-5.14%)
Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Stocks Plummet After Tech Earnings, Manufacturing Data ↗
The Dow Jones Industrial Average is down triple digits, while the S&P 500 Index eyes its worst daily percentage drop since September 2023. 
Via Talk Markets
Topics Stocks
News headline image
Bausch Health Responds to Market Rumors
Via ACCESSWIRE
News headline image
Bausch Health Welcomes Two New Members to the Executive Leadership Team
Via ACCESSWIRE
News headline image
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
Via ACCESSWIRE
News headline image
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
News headline image
BHC Stock Plunges as Bausch Health Appears on the Brink of Bankruptcy ↗
Although Bausch Health has denied rumors that it’s on the cusp of bankruptcy, BHC stock is nevertheless suffering from skepticism. 
Via InvestorPlace
Topics Bankruptcy
News headline image
Why Bausch health Shares Are Falling Today ↗
Bausch Health Companies Inc. (NYSE: BHC) is experiencing a sharp decline in its stock price Wednesday. The drop was triggered by a report suggesting the company is negotiating a potential prepackaged... 
Via Benzinga
Topics Bankruptcy
News headline image
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
Via ACCESSWIRE
News headline image
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
Via ACCESSWIRE
News headline image
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
Via ACCESSWIRE
News headline image
Why Bausch Health Companies Shares Are Falling After Q1 Results ↗
Bausch Health misses Q1 EPS estimates at 59 cents, despite a revenue increase of 11%. 
Via Benzinga
News headline image
Bausch Health Announces First Quarter 2024 Results
Via ACCESSWIRE
News headline image
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
News headline image
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Via ACCESSWIRE
News headline image
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
Via ACCESSWIRE
News headline image
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Via ACCESSWIRE
News headline image
Why Bausch Health Companies Stock Dived by More Than 7% Today ↗
A large red number on the bottom line attracted the wrong kind of investor attention for the company. 
Via The Motley Fool
News headline image
BHC Stock Earnings: Bausch Health Companies Misses EPS, Misses Revenue for Q1 2024 ↗
BHC stock results show that Bausch Health Companies missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Bausch Health to Announce First-Quarter 2024 Results on May 2
Via ACCESSWIRE
News headline image
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Via ACCESSWIRE
News headline image
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
Via ACCESSWIRE
News headline image
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
Via ACCESSWIRE
News headline image
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
News headline image
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
Via ACCESSWIRE
News headline image
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
Via ACCESSWIRE
News headline image
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
Via ACCESSWIRE
News headline image
Bausch Health Companies to Present at Cowen Annual Health Care Conference
Via ACCESSWIRE
News headline image
RBC Capital Maintains Sector Perform Rating for Bausch Health Companies: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.